- Primary research
- Open Access
Cycloartane-3,24,25-triol inhibits MRCKα kinase and demonstrates promising anti prostate cancer activity in vitro
© Lowe et al.; licensee BioMed Central Ltd. 2012
Received: 3 August 2012
Accepted: 10 November 2012
Published: 14 November 2012
Given the high occurrence of prostate cancer worldwide and one of the major sources of the discovery of new lead molecules being medicinal plants, this research undertook to investigate the possible anti-cancer activity of two natural cycloartanes; cycloartane-3,24,25-diol (extracted in our lab from Tillandsia recurvata) and cycloartane-3,24,25-triol (purchased). The inhibition of MRCKα kinase has emerged as a potential solution to restoring the tight regulation of normal cellular growth, the loss of which leads to cancer cell formation.
Kinase inhibition was investigated using competition binding (to the ATP sites) assays which have been previously established and authenticated and cell proliferation was measured using the WST-1 assay.
Cycloartane-3,24,25-triol demonstrated strong selectivity towards the MRCKα kinase with a Kd50 of 0.26 μM from a total of 451 kinases investigated. Cycloartane-3,24,25-triol reduced the viability of PC-3 and DU145 cell lines with IC50 values of 2.226 ± 0.28 μM and 1.67 ± 0.18 μM respectively.
These results will prove useful in drug discovery as Cycloartane-3,24,25-triol has shown potential for development as an anti-cancer agent against prostate cancer.
Prostate cancer is the second most frequently diagnosed cancer and sixth leading cause of cancer death in males, worldwide . The search for new molecules to combat the rising cases of prostate cancer especially those resistant to current chemotherapy calls for urgent action. Medicinal plants have been one of the major sources for the discovery of a number of current clinically used anticancer drugs.
Essential biological functions such as the provision of a structural frame work and the driving force for cellular motility and division are mediated by the actin cytoskeleton in all eukaryotic cells. A comprehensive overview of the biological processes that regulate the organization of actin is of recent interest to the regime of cancer therapy . Members of the Rho GTPase family such as myotonic dystrophy kinase-related Cdc42-binding kinases (MRCKα) are key regulators of the actin cytoskeleton and together with multiple target proteins safe guard the tight regulation of normal cell growth and differentiation [6, 7]. In the event of genomic alterations or carcinogenesis, eukaryotic cells become predispose to rapid and uncontrollable growth as evidenced by the elevated levels of LIMK1 kinase expressed in prostate cancer, a kinase which itself is activated by MRCKα . It is for this reason that inhibitors of these biochemical entities are thought to restore normal cell proliferation and provide a key solution to cancer treatment. The aim of this study therefore was to confirm the promising in vitro anti prostate cancer activity of 2 cycloartane isolates and their effect on prostate cancer related kinases, namely MRCKα.
Results and discussion
GTPases are activated by GTP exchange factors (GEFs) and down-regulated by GTPase-activating proteins (GAPs). Prolonged activation of these molecular entities can initiate a series of signal transduction pathways that can impinge on a number of cellular processes . Amongst the transducers of these signals are protein kinases and increase Rho signalling has been associated with tumour development and/or progression from various origins . The MRCKα kinase, an effector of CDC42 GTPase with functional overlap with ROCK1/2, has also been suggested to have a role in tumour progression  and/or invasion .
IC 50 results of WST-assay for PC-3 and DU145
Antiproliferation activity (IC50: μM)
Kinase inhibition (Kd50μM)
2.226 ± 0.28
1.67 ± 0.18
We report for the first time this inhibition of MRCKα kinase inhibition by cycloartane-3,24,25-triol. Of the 451 kinases, cycloartane-3,24,25-triol selectively inhibited MRCKα with greater potency than other potential chemotherapeutics. Our findings show that the bioactivity of this isolate not only inhibits MRCKα known to be associated with prostate cancer, but also reduced the viability of two prostate cancer cell lines, PC-3 and DU145 implicating the validity of these results in anti-cancer drug discovery.
Material and methods
The Cayman’s WTS-1assay kit which was used for the cell proliferation assay and kinase inhibition assay chemicals were purchased from Cayman Chemical Company.
Cell lines and culture medium
All cell lines with their respective media and supplements were obtained from ATCC (Manassas, VA, USA).
The cells (PC-3 and DU145) were maintained in minimum essential media (MEM) supplemented with 10% foetal calf serum (FCS), 20 mM l-glutamine, 2% penicillin–streptomycin, and 0.2% gentamicin. Cells were maintained at 37°C with 5% CO2 in Corning 75 cm3 culture flasks. Cells were trypsinized and plated at the appropriate density (500–2000 cells/well in log phase 72 h post drug addition) into 96 well plates in media for approximately 18 h after which they were exposed to cycloartanes; cycloart-23-ene-3,25-diol and cycloartane, cycloart-23-ene-3,25-triol for 72 h. The compounds were solubilized in DMSO (>0.1%). Following the appropriate treatments, cell proliferation was measured using the WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1, 3-benzene disulfonate) (Roche) colorimetric assay according to the manufacturer’s instructions . All assays were performed in duplicates and were monitored spectrophotometrically at 450 nm/690 nm (Synergy HT 96-well Plate Reader - BIO-TEK). Cell viability was assessed as percent of drugs relative to vehicle solvent-treated control. IC50 values were determined from the extract dose versus control growth curves using Graph Prism software.
Kinase inhibition assay
Plant material: Tillandsia recurvata (extraction and isolation)
The whole T. recurvata plant was collected from trees and electricity poles at Kingston, Jamaica. A voucher specimen of the plant was identified at the Institute of Jamaica Herbarium where it is deposited with Accession Number: IJ 3411. The collected plant material was air dried, pulverized into powder. 2.3 kg of Ball Moss biomass was extracted twice with 5 L of Chloroform. The filtrate was dried in a rotavapor to obtain a dark green residue (87.6 g).
Dr. Henry Lowe is a specialist in medicinal chemistry with approximately 50 years of experience in the field, he currently holds a PhD from the Manchester University, a M,Sc. from the University of Sydney and B.Sc. (hons) from UCWI, London University. He holds several postdoctoral studies including but not limited from; Harvard University and M.IT, USA. Dr. Simone Badal is currently a post-doctoral fellow at the Natural Products Institute, UWI, Mona where she recently completed her PhD (Biochemistry) in cancer research and holds a B.Sc. (hons) and M.Phil. in Biochemistry from the University of the West Indies, Mona. She also obtained her MBA in International Relations from the University of Wales, Cardiff. Ms. Charah Watson is a PhD candidate specialising in Natural products chemistry in the Department of Chemistry at the UWI, Mona. Her research activities include natural product isolation, elucidation and identification and their use as natural pest control and anti-cancer agents. Mr. Ngeh Toyang is a PhD candidate in Pharmacognosy with the Division of Pharmacognosy, Leiden University where his research focus is on cancer and HIV/AIDS. Dr. Joseph Bryant holds a Doctor of Veterinary Medicine degree from Tuskegee University specialising in cancer and HIV/AIDS research. A board certified Laboratory Animal Veterinarian with a background in Comparative Medicine, Dr. Bryant joined IHV from the National Institutes of Health.
The authors are grateful to Dr. Rena Lapidus of the Translational Core of the Greenebaum Cancer Center, University of Maryland School of Medicine for validating the results of the anticancer activity of Cycloartane-3,24,25-triol and to the KINOMEscan group (San Diego) for carrying out the kinase inhibition assays.
- Jemal A, Bray F, Center M, Jacques Ferlay M, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61: 69-90.View ArticlePubMedGoogle Scholar
- Lowe H: Anti-Tumor and Anti-Inflammatory Extracts of Plant Biomass and Their Uses. 2010, Jamaica, 1-14. US 7,713,556 B2Google Scholar
- Cabrera GM, Seldes AM: Hydroperoxycycloartanes from Til landsia recurvata. J Nat Prod. 1995, 58: 1920-1924.View ArticleGoogle Scholar
- Kikuchi T, Akihisa T, Tokuda H, Ukiya M, Watanabe K, Nishino H: Cancer chemopreventive effects of cycloartane-type and related triterpenoids in in vitro and in vivo models. J Nat Prod. 2007, 70: 918-922.View ArticlePubMedGoogle Scholar
- Hall A: Rho GTPases and the actin cytoskeleton. Science. 1998, 23: 509-514.View ArticleGoogle Scholar
- Heikkila T, Wheatley E, Crghton D, Schroder E, Boakes A, Kaye S, Mezna M, Pang L, Rushbrooke M, Turnbull A: Co-crystal structures of inhibitors with MRCKβ, a key regulator of tumor cell invasion. PloSOne. 2011, 6: 1-12.View ArticleGoogle Scholar
- Jaffe A, Hall A: RHO GTPASES: biochemistry and biology. Annu Rev Cell Dev Bi. 2005, 21: 247-269.View ArticleGoogle Scholar
- Sahai E, Marshall CJ: ROCK and Dia have opposing effects on adherens junctions downstream of Rho. Nat Cell Biol. 2002, 4: 408-412.View ArticlePubMedGoogle Scholar
- Benitaha SA, Valeróna PF, Aelstb L, Marshallc CJ, Lacala JC: Rho GTPases in human cancer: an unresolved link to upstream and downstream transcriptional regulation. Biochimica et Biophysica Acta. 2005, 1705: 121-132.Google Scholar
- Wilkinson S, Paterson HF, Marshall CJ: Cdc42–MRCK and Rho–ROCK signalling cooperate in myosin phosphorylation and cell invasion. Nat Cell Biol. 2005, 7: 255-261.View ArticlePubMedGoogle Scholar
- Terracciano D, Mazzarella C, Di Carlo A, Mariano A, Ferro M, Di Lorenzo G, Giordano A, Altieri V, De Placido S, Macchia V: Effects of the ErbB1/ErbB2 kinase inhibitor GW2974 on androgen-independent prostate cancer PC-3 cell line growth and NSE, chromogranin A and osteopontin content. Oncol Rep 2010. 2010, 24: 213-217.Google Scholar
- Rose D, Connolly J: Effects of fatty acids and eicosanoid synthesis inhibitors on the growth of two human prostate cancer cell lines. The Prostate. 1991, 18: 243-254.View ArticlePubMedGoogle Scholar
- Ngamwongsatit P, Banada PP, Panbangred W, Bhunia AK: WST-1-based cell cytotoxicity assay as a substitute for MTT-based assay for rapid detection of toxigenic Bacillus species using CHO cell line. J Microbiol Meth. 2008, 73: 211-215.View ArticleGoogle Scholar
- Fabian MA, Biggs WH, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG, Carter TA, Ciceri P, Edeen PT, Floyd M: A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol. 2005, 23: 329-336.View ArticlePubMedGoogle Scholar
- Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT: A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008, 26: 127-132.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.